News24
$IBO is emerging incalculably and investing its point$IBO is influencing auxiliary with fleetness on the TSX-V, as well as displaying a fantastic unit on the market, which was quite incredible!
universalibogaine inc Path Forward
Universal Ibogaine intends to acquire a network of addiction treatment clinics, licensing our treatment protocols to best in class treatment providers around the globe.
$IBO announced a vital addition of clinical trials director
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
$HEM declared the addition of an entirely closely-held subsidiar
Hemostemix recently declared the incorporation of PreCerv inc . (A totally closely-held subsidiary of Hemostemix). Hemostemix can grant PreCerv a world field of use licence for NCP-01 and its autologous somatic cell technology to treat central and peripheral systema nervosum diseases.
Hemostemix Inc. interest payment on convertible debenture
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
$IBO market cap improved $9.5 Million mark in the market$IBO has surpassed its market cap valuation again twice in a row and is persistently moving ahead the current cap valuation according to market context is $9.53 Million
$IBO is currently trading with enormous pace and is trying to disrupt its target price before time with every piece of effort it can foster, the shares are trading at $0.05